Please assess the completion status of the following clinical trial:

Trial Title: Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with moderate to severe chronic plaque psoriasis who receive a new prescription for alefacept~Exclusion Criteria:~* Subjects with a contraindication to alefacept~* Subjects with a history of cancer except for adequately treated basal cell carcinoma (maximum of 2 lesions)~* Subjects with any active cancer, including skin cancer~* Subjects having a serious local infection (eg. cellulitis, abscess) or serious systemic infection (eg. pneumonia, septicemia, tuberculosis), within the 3 months prior to the first dose of alefacept.~* Subjects known to be infected with the AIDS virus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. Amevive Exposure (Type: None): Canadian subjects with moderate to severe chronic plaque psoriasis

Based on this trial design, predict the completion outcome and termination type (if applicable).